Children's Hospital of Philadelphia at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Children's Hospital of Philadelphia brings 5 presentations to ASH 2026 in New Orleans, and exhibits at Booth 2221. Its program centres on non-cancer blood disorders, from sickle cell disease endpoints and iron balance to chronic neutropenia and heparin-induced clotting. It also covers using lipid nanoparticles to reach blood stem cells inside the body, and the case for lab-grown red cells in transfusion.
| Organization | ASH 2026 Attendance |
|---|---|
Children's Hospital of Philadelphia Philadelphia, PA | |
Pediatric hospital and research institute in Philadelphia, with major programs in pediatric hematology, sickle cell disease and cell and gene therapy. | Booth Exhibiting at Booth 2221 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia Pediatric-style regimens, asparaginase, immunotherapy, and CAR-T for teens and young adults with acute lymphoblastic leukemia, plus their psychosocial needs. Talk Lipid Nanoparticle (LNP) Delivery to Hematopoietic Stem Cells in Vivo Delivering mRNA and gene editors to blood stem cells inside the body with lipid nanoparticles, including editing before birth for inherited blood diseases. Talk Unmet Needs in Transfusion Medicine: Alloimmunization, Rare Blood Types, and the Case for Lab-Grown Red Cells Patients with rare blood types or antibodies against donor red cells struggle to find matches, and engineered lab-grown cells could supply tailored units. Talk Heparin-Induced Thrombocytopenia (HIT): How Heparin Sparks Thrombosis How the blood thinner heparin binds a platelet protein and provokes antibodies that drop platelet counts and paradoxically cause dangerous clots. Session Iron Homeostasis Across the Lifespan in Health and Disease Iron balance from fetal life to old age, what goes wrong in deficiency and overload, and the pathways being targeted to treat iron-related disorders. Session Unlocking Blood Disorders: Targeting Genetics to Identify Early Phenotypes Genomic tools and better disease models are changing how inherited blood disorders in children are found, understood, and managed. Session The Future of Clinical Endpoints in Sickle Cell Disease Better sickle cell disease trial endpoints than pain-crisis counts, such as biomarkers, combined measures, and patient-reported outcomes reflecting daily burden. |
Instantly find 20 buyers from Children's Hospital of Philadelphia
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction